Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. / Tarnow, Inge; Michelson, Alan D.; Barnard, Marc R.; Frelinger III, Andrew .L.; Aasted, Bent; Jensen, Berit R.; Parving, Hans-Henrik; Rossing, Peter; Tarnow, Lise.

In: Platelets, Vol. 20, No. 7, 2009, p. 513-519.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Tarnow, I, Michelson, AD, Barnard, MR, Frelinger III, AL, Aasted, B, Jensen, BR, Parving, H-H, Rossing, P & Tarnow, L 2009, 'Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity', Platelets, vol. 20, no. 7, pp. 513-519. https://doi.org/10.3109/09537100903221001

APA

Tarnow, I., Michelson, A. D., Barnard, M. R., Frelinger III, A. . L., Aasted, B., Jensen, B. R., Parving, H-H., Rossing, P., & Tarnow, L. (2009). Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets, 20(7), 513-519. https://doi.org/10.3109/09537100903221001

Vancouver

Tarnow I, Michelson AD, Barnard MR, Frelinger III AL, Aasted B, Jensen BR et al. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009;20(7):513-519. https://doi.org/10.3109/09537100903221001

Author

Tarnow, Inge ; Michelson, Alan D. ; Barnard, Marc R. ; Frelinger III, Andrew .L. ; Aasted, Bent ; Jensen, Berit R. ; Parving, Hans-Henrik ; Rossing, Peter ; Tarnow, Lise. / Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. In: Platelets. 2009 ; Vol. 20, No. 7. pp. 513-519.

Bibtex

@article{1f53be00590311df928f000ea68e967b,
title = "Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity",
abstract = "Patients with diabetes mellitus (DM) have increased platelet activation compared to non-diabetic controls. Platelet hyperreactivity has been associated with adverse cardiovascular outcomes in Type 2 DM, and with diabetic nephropathy. We investigated the relationship between platelet activation and nephropathy in Type 1 DM. Patients with Type 1 DM and diabetic nephropathy (n = 35), age- and sex-matched Type 1 DM patients with persistent normoalbuminuria (n = 51), and healthy age- and sex-matched controls (n = 30) were studied. Platelet surface P-selectin, platelet surface activated GPIIb/IIIa, monocyte-platelet aggregates (MPAs) and neutrophil-platelet aggregates (NPAs) were measured by whole blood flow cytometry as markers of platelet activation. Platelet reactivity was assessed in response to exogenously added ADP and thrombin receptor activating peptide (TRAP). Platelet surface P-selectin (basal and in response to 0.5 or 20 microM ADP) was higher in nephropathy patients compared with normoalbuminuric patients (P = 0.027), and non-diabetic controls (P = 0.0057). NPAs were higher in nephropathy patients compared to normoalbuminuric patients (P = 0.0088). MPAs were higher in nephropathy patients compared to non-diabetic controls (P = 0.0075). There were no differences between groups in activated GPIIb/IIIa or in response to TRAP at any end-point. More patients with nephropathy received aspirin (71.4%) compared to normoalbuminuric patients (27.4%) (P < 0.0001). Type 1 diabetic nephropathy, as compared with normoalbuminuria, is associated with circulating activated platelets and platelet hyperreactivity to ADP, despite the confounding variable of more nephropathy patients receiving aspirin. This platelet activation is likely to contribute to the known increased risk of cardiovascular events in patients with diabetic nephropathy",
author = "Inge Tarnow and Michelson, {Alan D.} and Barnard, {Marc R.} and {Frelinger III}, {Andrew .L.} and Bent Aasted and Jensen, {Berit R.} and Hans-Henrik Parving and Peter Rossing and Lise Tarnow",
year = "2009",
doi = "10.3109/09537100903221001",
language = "English",
volume = "20",
pages = "513--519",
journal = "Platelets",
issn = "0953-7104",
publisher = "Taylor & Francis",
number = "7",

}

RIS

TY - JOUR

T1 - Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity

AU - Tarnow, Inge

AU - Michelson, Alan D.

AU - Barnard, Marc R.

AU - Frelinger III, Andrew .L.

AU - Aasted, Bent

AU - Jensen, Berit R.

AU - Parving, Hans-Henrik

AU - Rossing, Peter

AU - Tarnow, Lise

PY - 2009

Y1 - 2009

N2 - Patients with diabetes mellitus (DM) have increased platelet activation compared to non-diabetic controls. Platelet hyperreactivity has been associated with adverse cardiovascular outcomes in Type 2 DM, and with diabetic nephropathy. We investigated the relationship between platelet activation and nephropathy in Type 1 DM. Patients with Type 1 DM and diabetic nephropathy (n = 35), age- and sex-matched Type 1 DM patients with persistent normoalbuminuria (n = 51), and healthy age- and sex-matched controls (n = 30) were studied. Platelet surface P-selectin, platelet surface activated GPIIb/IIIa, monocyte-platelet aggregates (MPAs) and neutrophil-platelet aggregates (NPAs) were measured by whole blood flow cytometry as markers of platelet activation. Platelet reactivity was assessed in response to exogenously added ADP and thrombin receptor activating peptide (TRAP). Platelet surface P-selectin (basal and in response to 0.5 or 20 microM ADP) was higher in nephropathy patients compared with normoalbuminuric patients (P = 0.027), and non-diabetic controls (P = 0.0057). NPAs were higher in nephropathy patients compared to normoalbuminuric patients (P = 0.0088). MPAs were higher in nephropathy patients compared to non-diabetic controls (P = 0.0075). There were no differences between groups in activated GPIIb/IIIa or in response to TRAP at any end-point. More patients with nephropathy received aspirin (71.4%) compared to normoalbuminuric patients (27.4%) (P < 0.0001). Type 1 diabetic nephropathy, as compared with normoalbuminuria, is associated with circulating activated platelets and platelet hyperreactivity to ADP, despite the confounding variable of more nephropathy patients receiving aspirin. This platelet activation is likely to contribute to the known increased risk of cardiovascular events in patients with diabetic nephropathy

AB - Patients with diabetes mellitus (DM) have increased platelet activation compared to non-diabetic controls. Platelet hyperreactivity has been associated with adverse cardiovascular outcomes in Type 2 DM, and with diabetic nephropathy. We investigated the relationship between platelet activation and nephropathy in Type 1 DM. Patients with Type 1 DM and diabetic nephropathy (n = 35), age- and sex-matched Type 1 DM patients with persistent normoalbuminuria (n = 51), and healthy age- and sex-matched controls (n = 30) were studied. Platelet surface P-selectin, platelet surface activated GPIIb/IIIa, monocyte-platelet aggregates (MPAs) and neutrophil-platelet aggregates (NPAs) were measured by whole blood flow cytometry as markers of platelet activation. Platelet reactivity was assessed in response to exogenously added ADP and thrombin receptor activating peptide (TRAP). Platelet surface P-selectin (basal and in response to 0.5 or 20 microM ADP) was higher in nephropathy patients compared with normoalbuminuric patients (P = 0.027), and non-diabetic controls (P = 0.0057). NPAs were higher in nephropathy patients compared to normoalbuminuric patients (P = 0.0088). MPAs were higher in nephropathy patients compared to non-diabetic controls (P = 0.0075). There were no differences between groups in activated GPIIb/IIIa or in response to TRAP at any end-point. More patients with nephropathy received aspirin (71.4%) compared to normoalbuminuric patients (27.4%) (P < 0.0001). Type 1 diabetic nephropathy, as compared with normoalbuminuria, is associated with circulating activated platelets and platelet hyperreactivity to ADP, despite the confounding variable of more nephropathy patients receiving aspirin. This platelet activation is likely to contribute to the known increased risk of cardiovascular events in patients with diabetic nephropathy

U2 - 10.3109/09537100903221001

DO - 10.3109/09537100903221001

M3 - Journal article

C2 - 19852691

VL - 20

SP - 513

EP - 519

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 7

ER -

ID: 19596234